Biosimilar Monoclonal Antibodies Market Report

Global and Region Biosimilar Monoclonal Antibodies Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 29, 2022
  • PAGES：231
  • REPORT CODE：GMM886123
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

    The report details the trend, potential and market size of Biosimilar Monoclonal Antibodies market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Biosimilar Monoclonal Antibodiesmarket, defines the market attractiveness level of Biosimilar Monoclonal Antibodies market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Biosimilar Monoclonal Antibodies industry, describes the types of Biosimilar Monoclonal Antibodies market, the applications of major players and the market size, and deeply analyzes the current situation of the global Biosimilar Monoclonal Antibodies market and the development prospects and opportunities of Biosimilar Monoclonal Antibodies industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Biosimilar Monoclonal Antibodies market in Chapter 13.

    By Player:

    • Torrent Pharmaceuticals

    • Novartis (Sandoz)

    • Hisun Pharma

    • Pfizer (Hospira)

    • Celltrion

    • Cadila Healthcare

    • 3SBIO

    • Celgen Biopharma

    • Dr Reddy’s

    By Type:

    • Infliximab

    • Rituximab

    • Trastuzumab

    • Adalimumab

    • Other

    By End-User:

    • Oncology

    • Autoimmune Disease

    • Other

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Biosimilar Monoclonal Antibodies Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Biosimilar Monoclonal Antibodies Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Biosimilar Monoclonal Antibodies Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Biosimilar Monoclonal Antibodies Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Biosimilar Monoclonal Antibodies Market Analysis and Outlook to 2022

    • 7.1 Global Biosimilar Monoclonal Antibodies Consumption (2017-2022)

    • 7.2 United States Biosimilar Monoclonal Antibodies Consumption (2017-2022)

    • 7.3 Europe Biosimilar Monoclonal Antibodies Consumption (2017-2022)

    • 7.4 China Biosimilar Monoclonal Antibodies Consumption (2017-2022)

    • 7.5 Japan Biosimilar Monoclonal Antibodies Consumption (2017-2022)

    • 7.6 India Biosimilar Monoclonal Antibodies Consumption (2017-2022)

    • 7.7 South Korea Biosimilar Monoclonal Antibodies Consumption (2017-2022)

    8 Region and Country-wise Biosimilar Monoclonal Antibodies Market Analysis and Outlook to 2028

    • 8.1 Global Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)

    • 8.2 United States Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)

    • 8.3 Europe Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)

    • 8.4 China Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)

    • 8.5 Japan Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)

    • 8.6 India Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)

    • 8.7 South Korea Biosimilar Monoclonal Antibodies Consumption Forecast (2022-2028)

    9 Global Biosimilar Monoclonal Antibodies Market Outlook by Types and Applications to 2022

    • 9.1 Global Biosimilar Monoclonal Antibodies Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Infliximab Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Rituximab Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Trastuzumab Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Adalimumab Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Other Consumption and Growth Rate (2017-2022)

    • 9.2 Global Biosimilar Monoclonal Antibodies Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Oncology Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Autoimmune Disease Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Other Consumption and Growth Rate (2017-2022)

    10 Global Biosimilar Monoclonal Antibodies Market Outlook by Types and Applications to 2028

    • 10.1 Global Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Infliximab Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Rituximab Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Trastuzumab Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Adalimumab Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.5 Global Other Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Oncology Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Autoimmune Disease Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Other Consumption Forecast and Growth Rate (2022-2028)

    11 Global Biosimilar Monoclonal Antibodies Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Biosimilar Monoclonal Antibodies Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Biosimilar Monoclonal Antibodies Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Biosimilar Monoclonal Antibodies Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Biosimilar Monoclonal Antibodies Market Competitive Analysis

    • 14.1 Torrent Pharmaceuticals

      • 14.1.1 Torrent Pharmaceuticals Company Details

      • 14.1.2 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product and Service

    • 14.2 Novartis (Sandoz)

      • 14.2.1 Novartis (Sandoz) Company Details

      • 14.2.2 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product and Service

    • 14.3 Hisun Pharma

      • 14.3.1 Hisun Pharma Company Details

      • 14.3.2 Hisun Pharma Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Hisun Pharma Biosimilar Monoclonal Antibodies Product and Service

    • 14.4 Pfizer (Hospira)

      • 14.4.1 Pfizer (Hospira) Company Details

      • 14.4.2 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product and Service

    • 14.5 Celltrion

      • 14.5.1 Celltrion Company Details

      • 14.5.2 Celltrion Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Celltrion Biosimilar Monoclonal Antibodies Product and Service

    • 14.6 Cadila Healthcare

      • 14.6.1 Cadila Healthcare Company Details

      • 14.6.2 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Product and Service

    • 14.7 3SBIO

      • 14.7.1 3SBIO Company Details

      • 14.7.2 3SBIO Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 3SBIO Biosimilar Monoclonal Antibodies Product and Service

    • 14.8 Celgen Biopharma

      • 14.8.1 Celgen Biopharma Company Details

      • 14.8.2 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Product and Service

    • 14.9 Dr Reddy’s

      • 14.9.1 Dr Reddy’s Company Details

      • 14.9.2 Dr Reddy’s Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Dr Reddy’s Biosimilar Monoclonal Antibodies Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Biosimilar Monoclonal Antibodies

    • Figure Biosimilar Monoclonal Antibodies Picture

    • Table Global Biosimilar Monoclonal Antibodies Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Biosimilar Monoclonal Antibodies Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Biosimilar Monoclonal Antibodies Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Biosimilar Monoclonal Antibodies Consumption by Country (2017-2022)

    • Figure United States Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Table Europe Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure China Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Japan Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure India Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure South Korea Biosimilar Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Global Biosimilar Monoclonal Antibodies Consumption Forecast by Country (2022-2028)

    • Figure United States Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Biosimilar Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Infliximab Consumption and Growth Rate (2017-2022)

    • Figure Global Rituximab Consumption and Growth Rate (2017-2022)

    • Figure Global Trastuzumab Consumption and Growth Rate (2017-2022)

    • Figure Global Adalimumab Consumption and Growth Rate (2017-2022)

    • Figure Global Other Consumption and Growth Rate (2017-2022)

    • Figure Global Oncology Consumption and Growth Rate (2017-2022)

    • Figure Global Autoimmune Disease Consumption and Growth Rate (2017-2022)

    • Figure Global Other Consumption and Growth Rate (2017-2022)

    • Figure Global Infliximab Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Rituximab Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Trastuzumab Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Adalimumab Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Oncology Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Autoimmune Disease Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Biosimilar Monoclonal Antibodies Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Biosimilar Monoclonal Antibodies Export by Region (Top 5 Countries) (2017-2028)

    • Table Torrent Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

    • Table Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product and Service

    • Table Novartis (Sandoz) (Foundation Year, Company Profile and etc.)

    • Table Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product and Service

    • Table Hisun Pharma (Foundation Year, Company Profile and etc.)

    • Table Hisun Pharma Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

    • Table Hisun Pharma Biosimilar Monoclonal Antibodies Product and Service

    • Table Pfizer (Hospira) (Foundation Year, Company Profile and etc.)

    • Table Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product and Service

    • Table Celltrion (Foundation Year, Company Profile and etc.)

    • Table Celltrion Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

    • Table Celltrion Biosimilar Monoclonal Antibodies Product and Service

    • Table Cadila Healthcare (Foundation Year, Company Profile and etc.)

    • Table Cadila Healthcare Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

    • Table Cadila Healthcare Biosimilar Monoclonal Antibodies Product and Service

    • Table 3SBIO (Foundation Year, Company Profile and etc.)

    • Table 3SBIO Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

    • Table 3SBIO Biosimilar Monoclonal Antibodies Product and Service

    • Table Celgen Biopharma (Foundation Year, Company Profile and etc.)

    • Table Celgen Biopharma Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

    • Table Celgen Biopharma Biosimilar Monoclonal Antibodies Product and Service

    • Table Dr Reddy’s (Foundation Year, Company Profile and etc.)

    • Table Dr Reddy’s Biosimilar Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

    • Table Dr Reddy’s Biosimilar Monoclonal Antibodies Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US